BAP Appetite Suppression via Hypothalamic Neuron Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective pharmaceutical treatments for obesity, with existing options being costly and only achieving modest weight reductions, and current research on hypothalamic neuronal subpopulations is hindered by their heterogeneous nature.
Innovation Solution
The use of N6-benzylaminopurine (BAP) as an appetite suppressant, administered in various forms, to target specific neuronal subpopulations in the hypothalamus, reducing body weight and altering gene expression in mice on high-fat diets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing pharmaceutical treatments are used for obesity, then weight reduction is achieved, but the treatments are costly and only achieve modest reductions
Solution Approach 1:
The patent uses a plant-derived cytokinin (BAP) as a low-cost alternative to expensive pharmaceutical treatments. BAP is a simple adenine derivative that can be produced through established plant hormone synthesis pathways, making it significantly cheaper than current obesity medications while maintaining effectiveness in reducing body weight and food intake.
Solution Approach 2:
The patent changes the chemical parameter from complex pharmaceutical compounds to a simple cytokinin structure (BAP). This structural simplification reduces manufacturing costs while the patent optimizes the dosage parameters (administered in concentrations of 10^-9 to 10^-6 M) to achieve effective weight reduction at low cost.
2Loss of information
If hypothalamic neuronal subpopulations are studied to understand obesity mechanisms, then appetite regulation is understood, but the heterogeneous nature of these neurons makes mechanistic studies difficult
Solution Approach 1:
The patent applies local quality by targeting specific hypothalamic neuronal subpopulations with BAP treatment. Rather than studying all hypothalamic neurons uniformly, the patent focuses on how BAP specifically affects appetite-regulating neurons (such as NPY/AgRP and POMC neurons), allowing mechanistic understanding without being overwhelmed by overall neuronal heterogeneity.
3Quantity of substance
If BAP is administered to reduce body weight, then weight loss and appetite suppression are achieved, but the mechanism of action in heterogeneous brain regions is difficult to determine
Solution Approach 1:
The patent uses BAP as an intermediary substance that can be tracked and measured. As a plant cytokinin with known chemical structure and properties, BAP serves as a measurable mediator that allows researchers to trace its effects through hypothalamic neurons and downstream signaling pathways, making the mechanism of action detectable despite brain region heterogeneity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BAP effectively reduces body weight and maintains weight loss in mice on high-fat diets by targeting hypothalamic neurons, improving glucose tolerance and insulin sensitivity, and modulating key neuropeptides involved in appetite regulation.
Implementation Method 1
Adenine-derived cytokinins, including kinetin, zeatin, and BAP, have been reported to act on mammalian cells via the P2 family of purine receptors, which endogenously bind a variety of purine derivatives, including ATP, ADP, and UDP
Data Source
AI summary
Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.